-
A critical view over the newest antidiabetic molecules in light of efficacy - a systematic review and meta-analysis [Elektronski vir]Salmen, Teodor ...The increase in life expectancy without a decrease in the years lived without disability leads to the rise of the population aged over 65 years prone to polypharmacy. The novel antidiabetic drugs can ... improve this global therapeutic and health problem in patients with diabetes mellitus (DM). We aimed to establish the efficacy (A1c hemoglobin reduction) and safety of the newest antidiabetic drugs (considered so due to their novelty in medical practice use), specifically DPP-4i, SGLT-2i, GLP-1 Ra, and tirzepatide. The present meta-analysis followed the protocol registered at Prospero with the CRD42022330442 registration number. The reduction in HbA1c in the DPP4-i class for tenegliptin was 95% CI −0.54 [−1.1, 0.01], p = 0.06; in the SGLT2-iclass for ipragliflozin 95% CI −0.2 [−0.87, 0.47], p = 0.55; and for tofogliflozin 95% CI 3.13 [−12.02, 18.28], p = 0.69, while for tirzepatide it was 0.15, 95% CI [−0.50, 0.80] (p = 0.65). The guidelines for treatment in type 2 DM are provided from cardiovascular outcome trials that report mainly major adverse cardiovascular events and data about efficacy. The newest antidiabetic non-insulinic drugs are reported to be efficient in lowering HbA1c, but this effect depends between classes, molecules, or patients’ age. The newest antidiabetic drugs are proven to be efficient molecules in terms of HbA1c decrease, weight reduction, and safety, but more studies are needed in order to characterize exactly their efficacy and safety profiles.Source: International journal of molecular sciences [Elektronski vir]. - ISSN 1422-0067 (Vol. 24, iss. 11, [article no.] 9760, 2023, str. 1-16)Type of material - e-article ; adult, seriousPublish date - 2023Language - englishCOBISS.SI-ID - 154457347
Author
Salmen, Teodor |
Serbanoiu, Liviu-Ionut |
Bica, Ioana-Cristina |
Serafinceanu, Cristian |
Muzurović, Emir |
Janež, Andrej, 1971- |
Busnatu, Stefan |
Banach, Maciej |
Rizvi, Ali Abbas |
Rizzo, Manfredi |
Pantea Stoian, Anca
Topics
novel antidiabetic noninsulinic drugs |
HbA1c |
efficacy |
nova antidiabetična neinsulinska zdravila |
HbA1c |
učinkovitost
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Salmen, Teodor | ![]() |
Serbanoiu, Liviu-Ionut | ![]() |
Bica, Ioana-Cristina | ![]() |
Serafinceanu, Cristian | ![]() |
Muzurović, Emir | ![]() |
Janež, Andrej, 1971- | 18372 |
Busnatu, Stefan | ![]() |
Banach, Maciej | ![]() |
Rizvi, Ali Abbas | ![]() |
Rizzo, Manfredi | ![]() |
Pantea Stoian, Anca | ![]() |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.